Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. März 2026 19:54 ET | Quelle: Robbins LLP

Soleno Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the SLNO Class Action

Robbins LLP is Investigating Allegations that Soleno Therapeutics(SLNO) Misled Investors Regarding the Viability and Efficacy of its Phase 3 Clinical Trial
09. März 2026 12:23 ET | Quelle: Robbins LLP

AQST Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aquestive Therapeutics, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Aquestive Therapeutics, Inc. (AQST) Misled Investors Regarding Approval of Anaphylm
05. März 2026 15:17 ET | Quelle: Robbins LLP

Robbins LLP Urges INO Stockholders Who Lost Money Investing in Inovio Pharmaceuticals, Inc. to Contact the Firm for Information About Leading the Class Action

Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device
18. Februar 2026 14:11 ET | Quelle: Robbins LLP

Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO

Robbins LLP is Investigating Allegations that Mereo BioPharma Group plc (MREO) Misled Investors Regarding Phase 3 Orbit and Cosmic Studies for Setrusumab
18. Februar 2026 14:07 ET | Quelle: Robbins LLP

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Robbins LLP is Investigating Allegations that Ultragenyx Pharmaceutical Inc. (RARE) Misled Investors Regarding Phase III Orbit and Cosmic Studies
13. Februar 2026 14:56 ET | Quelle: Robbins LLP

INO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Class Action

Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device
13. Februar 2026 13:17 ET | Quelle: Robbins LLP

VTGN Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Vistagen Therapeutics, Inc. (VTGN) Misled Investors Regarding the Viability of its Trial Study of Fasedieno
09. Februar 2026 16:06 ET | Quelle: Robbins LLP

RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ultragenyx Pharmaceutical Inc. Class Action

Robbins LLP is investigating claims that Ultragenyx (RARE) misled investors about Phase III Orbit and Cosmic trials for setrusumab.
04. Dezember 2025 14:46 ET | Quelle: Robbins LLP

TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX

TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX
25. November 2025 15:43 ET | Quelle: Robbins LLP

SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

Nächste Seite